Image Place holder

Kenneth F. Grossmann, MD, PhD

Specialty: Medical Oncology
Program: Cutaneous Oncology

Call 1-888-MOFFITT

Call 1-888-MOFFITT

Locations: Moffitt McKinley Outpatient Center

Cancer Types Treated: Melanoma

Dr. Kenneth Grossmann is an Associate Member in the Moffitt Cancer Center Department of Cutaneous Oncology. Dr. Grossmann received his PhD in Molecular and Medical Genetics and MD degree at Oregon Health Sciences University in Portland. He completed an Internal Medicine Residency at Oregon Health Sciences University before completing his Medical Oncology Fellowship at Oregon Health Sciences University and the University of Utah School of Medicine. Dr. Grosssmann was previously an Assistant Professor at the University of Utah/Huntsman Cancer Institute in Salt Lake City. He also served as the Co-Lead, Melanoma Clinical Research at Huntsman Cancer Institute. He has national leadership roles as Vice-Chairman of the Southwest Oncology Group Melanoma Committee and founding Co-Chair of Immunotherapy Resesarch Support Committee. Dr. Grossmann’s interests are care of patients with advanced melanoma and non-melanomatous skin cancer as an active investigator in the field of cutaneous oncology. His research interests include the treatment of surgically resected advanced melanoma with adjuvant immunotherapy, and the application of neo-adjuvant treatments to high-risk surgically resected disease. Fields of inquiry include immunotherapeutics, targeted therapies, mechanisms of tumor metastasis, and drugs that modify a tumor’s epigenetic profile. 

Education & Training

Board Certification:

  • Medical Oncology
  • Internal Medicine


  • Oregon Health Sciences University - Medical Oncology
  • University of Utah School of Medicine - Medical Oncology


  • Oregon Health Sciences University - Internal Medicine

Medical School:

  • Oregon Health Sciences University - MD
Participating Trials

Adjuvant Therapy with Pembrolizumab versus Placebo in Resected High-Risk Stage II Melanoma: A Randomized, Double-Blind Phase 3 Study (Keynote 716)
Condition: Cutaneous
Intervention: Pembrolizumab (Keytruda); Placebo

Phase 2 Study of Ceritinib in Patients with Unresectable Melanoma
Condition: Cutaneous
Intervention: Ceritinib (Zykadia)

Study of Resistance Mechanisms to Checkpoint Blockade
Condition: Cutaneous

A Phase 1/2a Dose Escalation and Cohort Expansion Study of the Safety, Tolerability, and Efficacy of Anti-LAG-3 Monoclonal Antibody (BMS-986016) Administered Alone and in Combination with Anti-PD-1 Monoclonal Antibody (Nivolumab, BMS-936558) in Advanced Solid Tumors
Condition: Cutaneous
Intervention: BMS-936558 (Nivolumab); BMS-986016 (Relatlimab); BMS-986213; Nivolumab

A Phase 3, Randomized, Open-label Study of NKTR-214 Combined with Nivolumab Versus Nivolumab in Participants with Previously Untreated Unresectable or Metastatic Melanoma
Condition: Cutaneous
Intervention: BMS-936558 (Nivolumab); NKTR-214; Nivolumab

If you believe you are eligible for one of these trials or studies, please call
813-745-6100 or toll-free 1-800-679-0775.


  • Bichakjian CK, Olencki T, Aasi SZ, Alam M, Andersen JS, Blitzblau R, Bowen GM, Contreras CM, Daniels GA, Decker R, Farma JM, Fisher K, Gastman B, Ghosh K, Grekin RC, Grossman K, Ho AL, Lewis KD, Loss M, Lydiatt DD, Messina J, Nehal KS, Nghiem P, Puzanov I, Schmults CD, Shaha AR, Thomas V, Xu YG, Zic JA, Hoffmann KG, Engh AM. Merkel Cell Carcinoma, Version 1.2018, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Ne. 2018 Jun;16(6):742-774. Pubmedid: 29891526.
  • Moser JC, Grossman KF. Adjuvant therapy for resected high-risk melanoma. Semin Cutan Med Surg. 2018 Jun;37(2):109-111. Pubmedid: 30040087.
  • Larkin J, Minor D, D'Angelo S, Neyns B, Smylie M, Miller WH, Gutzmer R, Linette G, Chmielowski B, Lao CD, Lorigan P, Grossmann K, Hassel JC, Sznol M, Daud A, Sosman J, Khushalani N, Schadendorf D, Hoeller C, Walker D, Kong G, Horak C, Weber J. Overall Survival in Patients With Advanced Melanoma Who Received Nivolumab Versus Investigator's Choice Chemotherapy in CheckMate 037: A Randomized, Controlled, Open-Label Phase III Trial. J Clin Oncol. 2018 Feb;36(4):383-390. Pubmedid: 28671856.
  • Grossman D, Farnham JM, Hyngstrom J, Klapperich ME, Secrest AM, Empey S, Bowen GM, Wada D, Andtbacka RHI, Grossmann K, Bowles TL, Cannon-Albright LA. Similar survival of patients with multiple versus single primary melanomas based on Utah Surveillance, Epidemiology, and End Results data (1973-2011). J Am Acad Dermatol. 2018 Aug;79(2):238-244. Pubmedid: 29499295.
  • Nebot N, Arkenau HT, Infante JR, Chandler JC, Weickhardt A, Lickliter JD, Sarantopoulos J, Gordon MS, Mak G, St-Pierre A, Tang L, Mookerjee B, Carson SW, Hayes S, Grossmann KF. Evaluation of the effect of dabrafenib and metabolites on QTc interval in patients with BRAF V600-mutant tumours. Br J Clin Pharmacol. 2018 Apr;84(4):764-775. Pubmedid: 29243287. Pmcid: PMC5867134.
  • Sowder JC, Cannon RB, Buchmann LO, Hunt JP, Hitchcock Y, Lloyd S, Grossmann KF, Monroe MM. Treatment-related determinants of survival in early-stage (T1-2N0M0) oral cavity cancer: A population-based study. Head Neck. 2017 May;39(5):876-880. Pubmedid: 28236368.
  • Schadendorf D, Wolchok JD, Hodi FS, Chiarion-Sileni V, Gonzalez R, Rutkowski P, Grob JJ, Cowey CL, Lao CD, Chesney J, Robert C, Grossmann K, McDermott D, Walker D, Bhore R, Larkin J, Postow MA. Efficacy and Safety Outcomes in Patients With Advanced Melanoma Who Discontinued Treatment With Nivolumab and Ipilimumab Because of Adverse Events: A Pooled Analysis of Randomized Phase II and III Trials. J Clin Oncol. 2017 Dec;35(34):3807-3814. Pubmedid: 28841387. Pmcid: PMC5791828.
  • Ray A, Williams MA, Meek SM, Bowen RC, Grossmann KF, Andtbacka RH, Bowles TL, Hyngstrom JR, Leachman SA, Grossman D, Bowen GM, Holmen SL, VanBrocklin MW, Suneja G, Khong HT. A phase I study of intratumoral ipilimumab and interleukin-2 in patients with advanced melanoma. Oncotarget. 2016 Sep;7(39):64390-64399. Pubmedid: 27391442. Pmcid: PMC5325451.
  • Hodi FS, Chesney J, Pavlick AC, Robert C, Grossmann KF, McDermott DF, Linette GP, Meyer N, Giguere JK, Agarwala SS, Shaheen M, Ernstoff MS, Minor DR, Salama AK, Taylor MH, Ott PA, Horak C, Gagnier P, Jiang J, Wolchok JD, Postow MA. Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial. Lancet Oncol. 2016 Nov;17(11):1558-1568. Pubmedid: 27622997. Pmcid: PMC5630525.
  • Bichakjian CK, Olencki T, Aasi SZ, Alam M, Andersen JS, Berg D, Bowen GM, Cheney RT, Daniels GA, Glass LF, Grekin RC, Grossman K, Higgins SA, Ho AL, Lewis KD, Lydiatt DD, Nehal KS, Nghiem P, Olsen EA, Schmults CD, Sekulic A, Shaha AR, Thorstad WL, Tuli M, Urist MM, Wang TS, Wong SL, Zic JA, Hoffmann KG, Engh A. Basal Cell Skin Cancer, Version 1.2016, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Ne. 2016 May;14(5):574-597. Pubmedid: 27160235.
  • Jimeno A, Posner MR, Wirth LJ, Saba NF, Cohen RB, Popa EC, Argiris A, Grossmann KF, Sukari A, Wilson D, Zhang X, Sun J, Glasser C, Attie KM, Sherman ML, Pandya SS, Weiss J. A phase 2 study of dalantercept, an activin receptor-like kinase-1 ligand trap, in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. Cancer. 2016 Dec;122(23):3641-3649. Pubmedid: 27648727.
  • Stenehjem DD, Toole M, Merriman J, Parikh K, Daignault S, Scarlett S, Esper P, Skinner K, Udager A, Tantravahi SK, Gill D, Straubhar AM, Agarwal AM, Grossmann KF, Samlowski WE, Redman B, Agarwal N, Alva A. Extension of overall survival beyond objective responses in patients with metastatic renal cell carcinoma treated with high-dose interleukin-2. Cancer Immunol Immun. 2016 Aug;65(8):941-949. Pubmedid: 27277816.
  • Anker CJ, Grossmann KF, Atkins MB, Suneja G, Tarhini AA, Kirkwood JM. Avoiding Severe Toxicity From Combined BRAF Inhibitor and Radiation Treatment: Consensus Guidelines from the Eastern Cooperative Oncology Group (ECOG). Int J Radiat Oncol Biol Phys. 2016 06;95(2):632-646. Pubmedid: 27131079. Pmcid: PMC5102246.
  • Grossmann KF. Adjuvant treatment for patients with surgically resected advanced-stage melanoma. Clin Adv Hematol Oncol. 2015 Oct;13(10):633-635. Pubmedid: 27058564.
  • Chen LA, Anker CJ, Hunt JP, Buchmann LO, Grossmann KF, Boucher K, Fang LM, Shrieve DC, Hitchcock YJ. Clinical outcomes associated with evolving treatment modalities and radiation techniques for base-of-tongue carcinoma: thirty years of institutional experience. Cancer Med. 2015 May;4(5):651-660. Pubmedid: 25620682. Pmcid: PMC4430258.
  • Postow MA, Chesney J, Pavlick AC, Robert C, Grossmann K, McDermott D, Linette GP, Meyer N, Giguere JK, Agarwala SS, Shaheen M, Ernstoff MS, Minor D, Salama AK, Taylor M, Ott PA, Rollin LM, Horak C, Gagnier P, Wolchok JD, Hodi FS. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med. 2015 May;372(21):2006-2017. Pubmedid: 25891304. Pmcid: PMC5744258.
  • Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, Schadendorf D, Dummer R, Smylie M, Rutkowski P, Ferrucci PF, Hill A, Wagstaff J, Carlino MS, Haanen JB, Maio M, Marquez-Rodas I, McArthur GA, Ascierto PA, Long GV, Callahan MK, Postow MA, Grossmann K, Sznol M, Dreno B, Bastholt L, Yang A, Rollin LM, Horak C, Hodi FS, Wolchok JD. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med. 2015 Jul;373(1):23-34. Pubmedid: 26027431. Pmcid: PMC5698905.
  • Pfeffer SR, Grossmann KF, Cassidy PB, Yang CH, Fan M, Kopelovich L, Leachman SA, Pfeffer LM. Detection of Exosomal miRNAs in the Plasma of Melanoma Patients. J Clin Med. 2015 Dec;4(12):2012-2027. Pubmedid: 26694476. Pmcid: PMC4693157.
  • Ly D, Bagshaw HP, Anker CJ, Tward JD, Grossmann KF, Jensen RL, Shrieve DC. Local control after stereotactic radiosurgery for brain metastases in patients with melanoma with and without BRAF mutation and treatment. J Neurosurg. 2015 Aug;123(2):395-401. Pubmedid: 25768829.
  • Weber JS, D'Angelo SP, Minor D, Hodi FS, Gutzmer R, Neyns B, Hoeller C, Khushalani NI, Miller WH, Lao CD, Linette GP, Thomas L, Lorigan P, Grossmann KF, Hassel JC, Maio M, Sznol M, Ascierto PA, Mohr P, Chmielowski B, Bryce A, Svane IM, Grob JJ, Krackhardt AM, Horak C, Lambert A, Yang AS, Larkin J. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2015 Apr;16(4):375-384. Pubmedid: 25795410.
  • Suttle AB, Grossmann KF, Ouellet D, Richards-Peterson LE, Aktan G, Gordon MS, LoRusso PM, Infante JR, Sharma S, Kendra K, Patel M, Pant S, Arkenau HT, Middleton MR, Blackman SC, Botbyl J, Carson SW. Assessment of the drug interaction potential and single- and repeat-dose pharmacokinetics of the BRAF inhibitor dabrafenib. J Clin Pharmacol. 2015 Apr;55(4):392-400. Pubmedid: 25449654.
  • Shprecher DR, Grossmann KF, Tward JD. Sustained remission of Parkinson disease associated melanoma with immunotherapy. Parkinsonism Relat Disord. 2014 Sep;20(9):1027-1029. Pubmedid: 24997547.
  • Duffy KL, Truong A, Bowen GM, Andtbacka RH, Hyngstrom J, Bowles T, Grossmann K, Khong H, Hyde M, Florell SR, Bowen AR, Wada D, Grossman D. Adequacy of 5-mm surgical excision margins for non-lentiginous melanoma in situ. J Am Acad Dermatol. 2014 Oct;71(4):835-838. Pubmedid: 25219711. Pmcid: PMC4167347.
  • Bichakjian CK, Olencki T, Alam M, Andersen JS, Berg D, Bowen GM, Cheney RT, Daniels GA, Glass LF, Grekin RC, Grossman K, Ho AL, Lewis KD, Lydiatt DD, Morrison WH, Nehal KS, Nelson KC, Nghiem P, Perlis CS, Shaha AR, Thorstad WL, Tuli M, Urist MM, Wang TS, Werchniak AE, Wong SL, Zic JA, Hoffmann KG, McMillian NR, Ho M. Merkel cell carcinoma, version 1.2014. J Natl Compr Canc Ne. 2014 Mar;12(3):410-424. Pubmedid: 24616545.
  • Terakedis BE, Anker CJ, Leachman SA, Andtbacka RH, Bowen GM, Sause WT, Grossmann KF, Bowles TL, Noyes RD, Hitchcock YJ, Boucher KM, Shrieve DC. Patterns of failure and predictors of outcome in cutaneous malignant melanoma of the scalp. J Am Acad Dermatol. 2014 Mar;70(3):435-442. Pubmedid: 24373782.
  • Alwan LM, Grossmann K, Sageser D, Van Atta J, Agarwal N, Gilreath JA. Comparison of acute toxicity and mortality after two different dosing regimens of high-dose interleukin-2 for patients with metastatic melanoma. Target Oncol. 2014 Mar;9(1):63-71. Pubmedid: 23609056.
  • Bichakjian CK, Olencki T, Alam M, Andersen JS, Berg D, Bowen GM, Cheney RT, Daniels GA, Glass LF, Grekin RC, Grossman K, Ho AL, Lewis KD, Lydiatt DD, Morrison WH, Nehal KS, Nelson KC, Nghiem P, Perlis CS, Shaha AR, Thorstad WL, Tuli M, Urist MM, Wang TS, Werchniak AE, Wong SL, Zic JA, McMillian N, Hoffman K, Ho M. Dermatofibrosarcoma protuberans, version 1.2014. J Natl Compr Canc Ne. 2014 Jun;12(6):863-868. Pubmedid: 24925197.
  • Ouellet D, Grossmann KF, Limentani G, Nebot N, Lan K, Knowles L, Gordon MS, Sharma S, Infante JR, Lorusso PM, Pande G, Krachey EC, Blackman SC, Carson SW. Effects of particle size, food, and capsule shell composition on the oral bioavailability of dabrafenib, a BRAF inhibitor, in patients with BRAF mutation-positive tumors. J Pharm Sci. 2013 Sep;102(9):3100-3109. Pubmedid: 23608920.
  • Grossmann AH, Yoo JH, Clancy J, Sorensen LK, Sedgwick A, Tong Z, Ostanin K, Rogers A, Grossmann KF, Tripp SR, Thomas KR, D'Souza-Schorey C, Odelberg SJ, Li DY. The small GTPase ARF6 stimulates β-catenin transcriptional activity during WNT5A-mediated melanoma invasion and metastasis. Sci Signal. 2013 Mar;6(265):ra14. Pubmedid: 23462101. Pmcid: PMC3961043.
  • Anker CJ, Ribas A, Grossmann AH, Chen X, Narra KK, Akerley W, Andtbacka RH, Noyes RD, Shrieve DC, Grossmann KF. Severe liver and skin toxicity after radiation and vemurafenib in metastatic melanoma. J Clin Oncol. 2013 Jun;31(17):e283-e287. Pubmedid: 23650406.
  • Andtbacka RH, Donaldson MR, Bowles TL, Bowen GM, Grossmann K, Khong H, Grossman D, Anker C, Florell SR, Bowen A, Duffy KL, Leachman SA, Noyes RD. Sentinel lymph node biopsy for melanoma in pregnant women. Ann Surg Oncol. 2013 Feb;20(2):689-696. Pubmedid: 23054111.
  • Grossmann KF, Colman H, Akerley WA, Glantz M, Matsuoko Y, Beelen AP, Yu M, De Groot JF, Aiken RD, Olson JJ, Olsen JJ, Evans BA, Jensen RL. Phase I trial of verubulin (MPC-6827) plus carboplatin in patients with relapsed glioblastoma multiforme. J Neurooncol. 2012 Nov;110(2):257-264. Pubmedid: 22932984.
  • Grossmann AH, Grossmann KF, Wallander ML. Molecular testing in malignant melanoma. Diagn Cytopathol. 2012 Jun;40(6):503-510. Pubmedid: 22619125.
  • Ascierto PA, Grimaldi AM, Curti B, Faries MB, Ferrone S, Flaherty K, Fox BA, Gajewski TF, Gershenwald JE, Gogas H, Grossmann K, Hauschild A, Hodi FS, Kefford R, Kirkwood JM, Leachmann S, Maio M, Marais R, Palmieri G, Morton DL, Ribas A, Stroncek DF, Stewart R, Wang E, Mozzillo N, Marincola FM. Future perspectives in melanoma research. Meeting report from the "Melanoma research: a bridge from Naples to the World. Napoli, December 5th-6th 2011". J Transl Med. 2012 Jul;10:83. Pubmedid: 22551296. Pmcid: PMC3390271.
  • Rai K, Sarkar S, Broadbent TJ, Voas M, Grossmann KF, Nadauld LD, Dehghanizadeh S, Hagos FT, Li Y, Toth RK, Chidester S, Bahr TM, Johnson WE, Sklow B, Burt R, Cairns BR, Jones DA. DNA demethylase activity maintains intestinal cells in an undifferentiated state following loss of APC. Cell. 2010 Sep;142(6):930-942. Pubmedid: 20850014. Pmcid: PMC2943938.
  • Grossmann KF, Ward AM, Matkovic ME, Folias AE, Moses RE. S. cerevisiae has three pathways for DNA interstrand crosslink repair. Mutat Res-Fund Mol M. 2001 Dec;487(3-4):73-83. Pubmedid: 11738934.
  • Grossmann KF, Ward AM, Moses RE. Saccharomyces cerevisiae lacking Snm1, Rev3 or Rad51 have a normal S-phase but arrest permanently in G2 after cisplatin treatment. Mutat Res-Fund Mol M. 2000 Sep;461(1):1-13. Pubmedid: 10980408.
  • Grossmann KF, Brown JC, Moses RE. Cisplatin DNA cross-links do not inhibit S-phase and cause only a G2/M arrest in Saccharomyces cerevisiae. Mutat Res-Fund Mol M. 1999 May;434(1):29-39. Pubmedid: 10377946.